This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Marra, G. & Boland, C.R. J. Natl Cancer Inst. 87, 1114–1125 (1995).
Mai, M. et al. Genomics 55, 341–344 (1999).
Behrens, J. et al. Science 280, 596–599 (1998).
Liu, W. et al. Nucleic Acids Res. 26, 1396–1400 (1998).
Boland, C.R. et al. Cancer Res. 58, 5248–5257 (1998).
Chan, E.F. et al. Nature Genet. 21, 410–413 (1999).
Ganguly, A. et al. Proc. Natl Acad. Sci. USA 90, 10325–10329 (1993).
Powell, S.M. et al. N. Engl. J. Med. 329, 1982–1987 (1993).
Ishitani, T. et al. Nature 399, 798–802 (1999).
Rampino, N. et al. Science 275, 967–969 (1997).
Miyashita, T. & Reed, J.C. Cell 80, 293–299 (1995).
Peifer, M. & Polakis, P. Science 287, 1606–1609 (2000).
Kishida, S. et al. Mol. Cell. Biol. 19, 4414–4422 (1999).
Satoh, S. et al. Nature Genet. 24, 245–250 (2000).
Acknowledgements
These studies were carried out with the support of funds from Mayo Clinic/Foundation to W.L. and by grants from the National Institutes of Health to D.I.S. (CA 48031) and S.N.T. (CA 60117).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, W., Dong, X., Mai, M. et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling. Nat Genet 26, 146–147 (2000). https://doi.org/10.1038/79859
Issue Date:
DOI: https://doi.org/10.1038/79859
This article is cited by
-
β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer
Journal of Translational Medicine (2023)
-
A novel pathogenic frameshift variant in AXIN2 in a man with polyposis and hypodontia
Hereditary Cancer in Clinical Practice (2023)
-
Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
Journal of Cancer Research and Clinical Oncology (2023)
-
Suppression of Wnt/β-Catenin Signaling Is Associated with Downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer’s Disease
Molecular Neurobiology (2023)
-
Clone wars: From molecules to cell competition in intestinal stem cell homeostasis and disease
Experimental & Molecular Medicine (2022)